Antibodies for treatment of cancer expressing claudin 6

Patent metadata

Field	Value
Publication number	US-10919974-B2
Application number	US-201816028210-A
Country	US
Kind code	B2
Filing date	Jul 5, 2018
Priority date	May 13, 2011
Publication date	Feb 16, 2021
Grant date	Feb 16, 2021

Abstract

The present invention provides antibodies useful as therapeutics for treating and/or preventing diseases associated with cells expressing CLDN6, including tumor-related diseases such as ovarian cancer, lung cancer, gastric cancer, breast cancer, hepatic cancer, pancreatic cancer, skin cancer, malignant melanoma, head and neck cancer, sarcoma bile duct cancer, cancer of the urinary bladder, kidney cancer, colon cancer, placental choriocarcinoma, cervical cancer, testicular cancer, and uterine cancer.

First claim

The invention claimed is:

1. A method of producing an antibody, or an antigen binding fragment thereof, that binds to CLDN6, the method comprising the steps of:
(a) culturing a human host cell transformed with one or more expression vectors under conditions in which the host cell expresses the antibody or antigen binding fragment thereof; and
(b) harvesting a preparation of the antibody or antigen binding fragment thereof expressed by the human host cell;
wherein the one or more expression vectors comprise:
(i) a nucleic acid sequence encoding a polypeptide comprising the antibody heavy chain CDR1, CDR2, and CDR3 regions having the amino acid sequences of positions 26-33, positions 51-58, and positions 97-106 of SEQ ID NO: 36, respectively; and a nucleic acid sequence encoding a polypeptide comprising the antibody light chain CDR1, CDR2, and CDR3 regions having the amino acid sequences of positions 27-31, positions 49-51, and positions 88-97 of SEQ ID NO: 35, respectively.

2. The method of claim 1 , wherein the antigen binding fragment is a Fab, F(ab′) 2 , Fv, or single chain Fv.

3. The method of claim 1 , wherein the human host cell is a lymphocytic cell.

4. A recombinant nucleic acid comprising:
a first nucleic acid sequence encoding a first polypeptide comprising heavy chain CDR1, CDR2, and CDR3 regions having the amino acid sequences of positions 26-33, positions 51-58, and positions 97-106 of SEQ ID NO: 36, respectively; and a second nucleic acid sequence encoding a second polypeptide comprising light chain CDR1, CDR2, and CDR3 regions have the amino acid sequences of positions 27-31, positions 49-51, and positions 88-97 of SEQ ID NO: 35, respectively.

5. A human cell expressing the first and second polypeptides encoded by the recombinant nucleic acid of claim 4 .

6. The recombinant nucleic acid of claim 4 , further comprising a third nucleic acid sequence encoding a linker for joining the first polypeptide and the second polypeptide.

7. The recombinant nucleic acid of claim 4 , wherein the first polypeptide comprises a heavy chain variable region having the amino acid sequence of SEQ ID NO: 36 and the second polypeptide comprises a light chain variable region having the amino acid sequence of SEQ ID NO: 35.

8. A transformed host cell comprising one or more expression vectors, the one or more expression vectors comprising:
a first nucleic acid sequence encoding a first polypeptide comprising heavy chain CDR1, CDR2, and CDR3 regions having the amino acid sequences of positions 26-33, positions 51-58, and positions 97-106 of SEQ ID NO: 36, respectively; and a second nucleic acid sequence encoding a second polypeptide comprising light chain CDR1, CDR2, and CDR3 regions have the amino acid sequences of positions 27-31, positions 49-51, and positions 88-97 of SEQ ID NO: 35, respectively.

9. The transformed host cell of claim 8 , wherein the first polypeptide comprises a heavy chain variable region having the amino acid sequence of SEQ ID NO: 36 and the second polypeptide comprises a light chain variable region having the amino acid sequence of SEQ ID NO: 35.

10. The transformed host cell of claim 8 , wherein the host cell is a human cell.

11. The transformed host cell of claim 8 , wherein the host cell is a lymphocytic cell.

12. The transformed host cell of claim 8 , wherein the one or more expression vectors further comprise a third nucleic acid sequence encoding a linker for joining the first polypeptide and the second polypeptide.

Assignees

• Ganymed Pharmaceuticals Ag
• Univ Mainz Johannes Gutenberg
• Ganymed Pharmaceuticals Gmbh

Inventors

• Sahin Ugur
• Tureci Ozlem
• Koslowski Michael
• Walter Korden
• Woll Stefan
• Kreuzberg Maria
• Hubner Bernd
• Erdeljan Michael
• Weichel Michael

Classifications

• C07K2317/92

  Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value · CPC title

• C07K2317/24

  containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered · CPC title

• A61P35/00

  Antineoplastic agents · CPC title

• A61K2039/505

  comprising antibodies · CPC title

• C07K2317/76

  Antagonist effect on antigen, e.g. neutralization or inhibition of binding · CPC title